A targeted genetics approach to mitigate β-1,4-GalT-V gene protein expression using shRNA for β-1,4-GalT-V has been used successfully to mitigate VEGF-induced angiogenesis in cultured human umbilical vein endothelial cells [9] and there was a reduction in tumor growth in a mouse model of glioblastoma [26]. This evidence concerns the gene VEGFA and neoplasm.